Evaluation of Postoperative Adjuvant Chemotherapy Efficacy for Bladder Cancer Based on Organoid Technology.

To evaluate the clinical efficacy of using tumor organoid drug sensitivity experiments to guide postoperative adjuvant chemotherapy in patients with muscle-invasive bladder cancer, and to assess the application value of tumor organoid drug sensitivity experiments in guiding individualized postoperative adjuvant chemotherapy for muscle-invasive bladder cancer.

NCT Number	NCT07379255
Lead Sponsor	Qilu Hospital of Shandong University Collaborators: The Second Hospital of Shandong University, Qianfoshan Hospital, Shandong Provincial Hospital, Shandong Province Third hospital, Taian City Central Hospital, Weifang People's Hospital, Binzhou Medical University, The Affiliated Hospital of Qingdao University, Jining First People's Hospital, Liaocheng People's Hospital, Linyi People's Hospital, Yantai Yuhuangding Hospital, Zibo Central Hospital, Dezhou Hospital Qilu Hospital of Shandong University, Zaozhuang Municipal Hospital, Qilu Hospital of Shandong University (Qingdao)
Conditions	Bladder Cancer
Enrollment	266 participants
Start Date	2025-01-01
Primary Completion	2030-12-31 (estimated)
Study Completion	2030-12-31 (estimated)
Updated on ClinicalTrials.gov	2026-01-30